PaxVax and Valneva will market each other's cholera and typhoid vaccines; Scripps wins $4.5M from Gates Foundation for HIV/AIDS vaccine;

> PaxVax and Valneva have entered into an agreement to market their cholera and typhoid vaccines. PaxVax will market Valneva's Dukoral in Italy, Spain and Portugal, and Valneva will market PaxVax's Vivotif in Canada, Sweden, Norway, Denmark and Finland. Release

> The Scripps Research Institute won two grants from the Bill & Melinda Gates Foundation totaling more than $4.5 million to fund the development of an HIV/AIDS vaccine. Release

> Gaithersburg, MD-based Vaxin announced the enrollment of its first patient into a Phase I trial of HepTcell, its hepatitis B candidate. Release

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.